NYSEAMERICAN:PLX - Protalix Biotherapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.56 +0.01 (+1.82 %) (As of 10/24/2018 01:28 AM ET)Previous Close$0.56Today's Range$0.54 - $0.5852-Week Range$0.38 - $0.83Volume269,100 shsAverage Volume747,963 shsMarket Capitalization$308.37 millionP/E RatioN/ADividend YieldN/ABeta0.97 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel. Receive PLX News and Ratings via Email Sign-up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:PLX Previous SymbolNYSEMKT:PLX CUSIPN/A Webwww.protalix.com Phone+972-4-9028100 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees190 Outstanding Shares148,360,000Market Cap$308.37 million OptionableOptionable Protalix Biotherapeutics (NYSEAMERICAN:PLX) Frequently Asked Questions What is Protalix Biotherapeutics' stock symbol? Protalix Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PLX." How were Protalix Biotherapeutics' earnings last quarter? Protalix Biotherapeutics Inc (NYSEAMERICAN:PLX) announced its earnings results on Thursday, August, 9th. The company reported ($0.08) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.05) by $0.03. The company had revenue of $2.01 million for the quarter, compared to analyst estimates of $7 million. View Protalix Biotherapeutics' Earnings History. When is Protalix Biotherapeutics' next earnings date? Protalix Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 14th 2018. View Earnings Estimates for Protalix Biotherapeutics. What price target have analysts set for PLX? 1 analysts have issued 1-year price targets for Protalix Biotherapeutics' shares. Their forecasts range from $4.00 to $4.00. On average, they expect Protalix Biotherapeutics' share price to reach $4.00 in the next twelve months. This suggests a possible upside of 614.3% from the stock's current price. View Analyst Price Targets for Protalix Biotherapeutics. What is the consensus analysts' recommendation for Protalix Biotherapeutics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Protalix Biotherapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Protalix Biotherapeutics. What are Wall Street analysts saying about Protalix Biotherapeutics stock? Here are some recent quotes from research analysts about Protalix Biotherapeutics stock: 1. According to Zacks Investment Research, "Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. " (10/16/2018) 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our model yields an rNPV of $213M for PRX-102 using a 15% discount rate and 75% probability of approval, accounting for the Chiesi partnership and receipt of royalties on PRX-102 sales globally. We also ascribe an rNPV of $200M to alidornase alfa, a $100M rNPV for $50M rNPV for OPRX-106, translating into a price per share of $4.00. This assumes 148M shares outstanding as of end-2Q 2019." (9/24/2018) Are investors shorting Protalix Biotherapeutics? Protalix Biotherapeutics saw a increase in short interest during the month of September. As of September 28th, there was short interest totalling 2,454,761 shares, an increase of 82.6% from the September 14th total of 1,344,316 shares. Based on an average trading volume of 1,851,647 shares, the days-to-cover ratio is presently 1.3 days. Approximately 1.8% of the company's stock are sold short. View Protalix Biotherapeutics' Current Options Chain. Who are some of Protalix Biotherapeutics' key competitors? Some companies that are related to Protalix Biotherapeutics include Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Neptune Wellness Solutions (NEPT) and Monash IVF Group (MVF). Who are Protalix Biotherapeutics' key executives? Protalix Biotherapeutics' management team includes the folowing people: Mr. Moshe Manor, Chief Exec. Officer, Pres and Director (Age 62)Dr. Yoseph Shaaltiel Ph.D., Founder and Exec. VP of R&D (Age 64)Mr. Yossi Maimon CPA, MBA, Chief Financial Officer, VP, Treasurer and Sec. (Age 47)Dr. Einat Brill-Almon Ph.D., Sr. VP of Product Devel. (Age 58)Mr. Yaron Naos, Sr. VP of Operations (Age 55) How do I buy shares of Protalix Biotherapeutics? Shares of PLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Protalix Biotherapeutics' stock price today? One share of PLX stock can currently be purchased for approximately $0.56. How big of a company is Protalix Biotherapeutics? Protalix Biotherapeutics has a market capitalization of $308.37 million. Protalix Biotherapeutics employs 190 workers across the globe. What is Protalix Biotherapeutics' official website? The official website for Protalix Biotherapeutics is http://www.protalix.com. How can I contact Protalix Biotherapeutics? Protalix Biotherapeutics' mailing address is 2 Snunit St, Science Park, Pob 455, KARMIEL, 20100, Israel. The company can be reached via phone at +972-4-9028100. MarketBeat Community Rating for Protalix Biotherapeutics (NYSEAMERICAN PLX)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 123 (Vote Outperform)Underperform Votes: 127 (Vote Underperform)Total Votes: 250MarketBeat's community ratings are surveys of what our community members think about Protalix Biotherapeutics and other stocks. Vote "Outperform" if you believe PLX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/24/2018 by MarketBeat.com StaffFeatured Article: What are the Different Types of Leveraged Buyouts?